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Abstract
Background: To assess differences in outpatient costs among pharmaceutically treated diabetes patients with and
without a diagnosis of depression in a Dutch primary care setting.
Methods: A retrospective case control study over 3 years (2002-2004). Data on 7128 depressed patients and 23772
non-depressed matched controls were available from the electronic medical record system of 20 general practices
organized in one large primary care organization in the Netherlands. A total of 393 depressed patients with
diabetes and 494 non-depressed patients with diabetes were identified in these records. The data that were
extracted from the medical record system concerned only outpatient costs, which included GP care, referrals, and
medication.
Results: Mean total outpatient costs per year in depressed diabetes patients were €1039 (SD 743) in the period
2002-2004, which was more than two times as high as in non-depressed diabetes patients (€492, SD 434). After
correction for age, sex, type of insurance, diabetes treatment, and comorbidity, the difference in total annual costs
between depressed and non-depressed diabetes patients changed from €408 (uncorrected) to €463 (corrected) in
multilevel analyses. Correction for comorbidity had the largest impact on the difference in costs between both
groups.
Conclusions: Outpatient costs in depressed patients with diabetes are substantially higher than in non-depressed
patients with diabetes even after adjusting for confounders. Future research should investigate whether effective
treatment of depression among diabetes patients can reduce health care costs in the long term.
Background
Depression is common in primary care with prevalence
rates ranging from 5% to 10% [1] and has a substantial
impact on quality of life and societal costs [2,3]. In peo-
ple with diabetes increased depression rates are found in
comparison with people without diabetes [4].
Depression in combination with diabetes as compared
with diabetes alone, has been linked with poor self-care
and adherence to medical treatment,[5] poorer glycemic
control,[6] more diabetes complications,[7] and a higher
risk of morbidity and all cause mortality [8]. Moreover,
comorbid depression and diabetes is associated with
increased health care costs in comparison with diabetes
alone [9,10].
Most depressed patients and diabetes patients are
treated in primary care. In a recent retrospective study,
we showed that diabetes was almost 3 times as prevalent
in treated depressed patients than in matched controls
in primary care [11]. Since both the numbers of patients
with depression and of patients with diabetes are
increasing rapidly worldwide and both conditions are
associated with raised health care costs, it is important
to examine the relation between depression, diabetes
and costs.
Several studies determined the prevalence of depres-
sion in diabetes populations and subsequently evaluated
costs [9,10]. In a large USA sample of adult health plan
members with diabetes, depression was associated with
50-75% increase in health services use [9]. In a primary-
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care-based sample of patients with type 1 and 2 dia-
betes, higher levels of depressive symptom severity were
associated with increased health care costs compared
with patients with low-severity depressive symptoms
[10]. Whereas the majority of other studies assessed the
presence of depressive symptoms using questionnaires
in a diabetes population, our study is unique in the
sense that it was done in a very large primary care data-
base using selection criteria based on objective informa-
tion registered by the GP. The aim of the study was to
compare differences in resource use and health care
costs between pharmaceutically treated diabetes patients
with and without depression who were identified in a
primary care cohort from the Netherlands while correct-
ing for age, sex and comorbidity.
Methods
Design
This was a retrospective case control study over 3 years
(2002-2004). In a cohort of depressed patients and their
non-depressed matched controls diabetes patients were
identified. The objective of this study was to investigate
differences in outpatient costs between pharmaceutically
treated diabetes patients with and without depression.
Ethics statement
The study has been conducted according to the princi-
ples expressed in the Declaration of Helsinki. The study
was approved by the scientific council of the Primary
Health Care Organisation Almere. The data were ana-
lyzed anonymously. Therefore, no ethical approval was
necessary for this project.
Data collection
Data were retrieved from electronic medical records
kept by 20 general practices organized in one large pri-
mary care organization in Almere. Almere is a munici-
pality in the centre region of the Netherlands with
approximately 184,400 citizens (7 July 2008). All primary
care practices and pharmacies in Almere are organized
in one central health organization and share the same
electronic medical record system saved in one central
database. Data in this system include information on
consultations, diagnoses, referrals and prescriptions.
Diagnoses are recorded using the ICPC-2 coding system
(International Classification of Primary Care). Drugs are
classified according to the Anatomical Therapeutic Che-
mical (ATC) classification system. In the ATC classifica-
tion system which is maintained by the WHO, the
active substances of drugs are divided into different
groups according to the organ or system on which they
act and their chemical, pharmacological and therapeutic
properties.
The Dutch health care system is based on the princi-
ple that everybody has adequate access to health care.
Almost everyone in The Netherlands is registered with a
general practitioner. Until 2006 two forms of insurance
existed in The Netherlands: private and social insurance.
People with earnings above approximately €30,000 per
year and their dependants were excluded from statutory
coverage provided by public sickness funds and could
purchase coverage from private health insurers.
Patient selection
The patient selection procedure is depicted in Figure 1
and described here. In the study period (2002 to 2004),
a total of 229,782 patients were registered at the 20 pri-
mary care practices. Depressed patients were selected
according to the following criteria: 1) use of antidepres-
sants in the period 2002-2004 (ATC code N06A) or
referral to a mental health professional (psychiatrist,
psychologist, social worker, psychotherapist or regional
institute for mental welfare) and 2) a diagnosis of
depressive complaints or depression (ICPC code P03 or
P76). In this way, 7,128 treated depressed patients were
identified. Controls consisting of registered patients at
the same primary care practices as depressed patients.
To ensure comparability between depressed patients and
controls, controls were matched with depressed patients
based on year and month of birth, sex, and general
practitioner (GP). This resulted in 23,772 matched con-
trols and a total study population of 30,900 patients.
The number of matched controls per depressed patient
varied with age from 4 in the age group 31-40 years to
1 in the age group > 90 years.
Subsequently, in this population of 30,900 primary care
patients diabetes patients were identified. Patients were
classified as having diabetes when they received pharma-
ceutical treatment consisting of insulin (ATC code A10A)
and/or oral blood glucose lowering drugs (ATC code
A10B). In this study sample, a diagnosis of diabetes was
based on medication data and not on diagnostic codes.
Medication data rather than problem lists were used,
because problem lists (a list of clinically relevant, current
health problems of the patient coded using the ICPC-2)
may not be reliable and/or up to date. This means that it
was not possible to discriminate between diabetes mellitus
types 1 and 2 and that patients treated by lifestyle advices
only are not included. A total of 393 (5.5%) depressed
patients with diabetes was identified and 494 (2.1%) non-
depressed patients with diabetes resulting in 1 to 2 non-
depressed patients per depressed patient.
Co-morbidity
To define co morbidity a Dutch adaptation [12] of the
revised chronic disease score (CDS) was used [13]. The
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CDS is a measure of chronic disease status and uses
ATC codes from automated pharmacy data as an indica-
tor for the presence of certain chronic conditions. The
following 25 conditions are distinguished: coronary and
peripheral vascular disease, epilepsy, hypertension, HIV/
AIDS, tuberculosis, rheumatologic conditions, hyperlipi-
demia, malignancies, Parkinson’s disease, renal disease
(including end stage renal disease), cardiac disease/arter-
iosclerotic cardiovascular disease/congestive heart fail-
ure, diabetes, glaucoma, peptic acid disease, cystic
fybrosis, transplantations, respiratory illness/asthma,
thyroid disorders, gout, Crohn’s and ulcerative colitis,
pain and inflammation, pain, depression, psychotic ill-
ness (including bipolar disorders), anxiety and tension.
Diabetes and depression were excluded from the ana-
lyses concerning comorbidity.
Health care utilization
The data that were extracted from the medical record
system concerned only outpatient costs, which included
GP care, referrals, and medication. Costs were not
restricted to diabetes only but considered all causes. In
case of a referral by the GP, data on the duration of
treatment were lacking. Therefore, the average number
of treatment sessions was obtained from reports on
health care utilization of Dutch national organizations
(Table 1) [14-22].
Costs
Costs were calculated using Dutch guidelines for cost
studies. If available, Dutch standard costs were used to
value health care utilization [21,22]. Otherwise, prices
from health care providers themselves, prices from pro-
fessional organizations or tariffs were used. Medication
costs were estimated using prices from the pharmacy
database of the Royal Dutch Society for Pharmacy [23].
For drugs of which 300 units or more were delivered
the specific price was obtained from the pharmacy data-
base. For all other drugs the median of the obtained
drug prices, which was to €0.19 per unit, was used. All
prices were adjusted to the year 2003 using consumer
price indices [20]. Table 1 lists the unit costs used in
this cost-of-illness study.
Analysis
In all analyses depressed patients with diabetes were
compared with non-depressed patients with diabetes.
Healthcare utilization was dichotomized according to
whether a patient visited a specific provider yes or no.
These rates were compared using logistic binary
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regression while correcting for age and sex. Costs gener-
ally have a highly skewed distribution caused by many
patients with low costs and few patients with high costs
[24]. Therefore, bias-corrected and accelerated boot-
strapping with 1000 replications was used to compare
costs between the two groups [25]. Bootstrapping was
performed using StataSE 10 for Windows (Stata Corp
LP, USA).
Patients in this study were clustered within GPs. It is
reasonable to assume that patients between GPs differ
in some characteristics, for example personality charac-
teristics of the GP. Multilevel modelling is a statistical
technique that can be used to correct for this clustering.
The clustering in this study was modest (ICC 0.06), but
we still decided to correct for clustering. Therefore, a
random intercept was added to the multilevel models
with group (depressed or non-depressed) as the central
determinant to correct for clustering of patients within
GPs. Total costs were adjusted for potential confound-
ing by age, sex, type of insurance and medical comor-
bidity in the multilevel analyses to be able to estimate
the effect of being depressed on outpatient costs among
diabetes patients as unbiased as possible. All conditions
distinguished by the CDS except depression and dia-
betes were included in the model as being present or
not. In 2002-2004 patients could have private or social
insurance. Private insurance indicates a higher socioeco-
nomic status. Therefore, type of insurance was also
included. The multilevel models were subsequently
bootstrapped (1000 replications) and bias-corrected and
accelerated confidence intervals were estimated. The
multilevel analyses and bootstrapping were performed in
StataSE 10 for Windows (Stata Corp LP, USA).
Results
Study sample
Depressed patients with diabetes were older and had
more comorbid conditions than non-depressed patients
with diabetes, whereas diabetes treatment (oral antidia-
betics and insulin) did not differ (Table 2).
Health care utilization
Table 3 shows the health care utilization rates in
depressed and non-depressed patients with diabetes.
Depressed patients with diabetes were more often
referred to all health care providers than non-
depressed patients with diabetes. Ninety-eight percent
of all patients in both groups visited their GP at least
once in 2002-2004. Significantly more depressed
patients with diabetes were referred to an outpatient
Table 1 Mean number of contacts and unit costs in Euros for the year 2003.
Number of contacts Unit cost (€, 2003)
Contacts with the GP
Consultation* – 20.20a
Consultation, long duration* – 40.40a
Home visit* – 40.40a
Home visit, long duration* – 80.80a
Telephone contact* – 10.10a
Repeat prescription* – 10.10a
Physiotherapy†‡ 11.0 or 13.1 22.75a
Dietician 5.0 14.07b
Mental health care
Social worker† 7.5 47.86c
Psychologist† 13.0 76.00a
Psychiatrist† 13.0§ 76.00a
Psychotherapist† 13.0§ 76.00a
Regional institute for mental 16.0 124.00a
welfare†
Outpatient clinic|| 4.1 56.00a
Medication – dependent on drug & dose
* exact number of contacts available from the medical record system
†estimated number of sessions per referral
‡depending on type of insurance (private or public insurance)
§ assumed to be the same as for a psychologist
||estimated number of sessions per patient per year
a Dutch standard cost [21,22]
b mean price obtained from professionals
c price according to professional organisation
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clinic during the three years of the study than non-
depressed patients with diabetes (89% versus 78%,
respectively; OR = 2.5, p < 0.001). Thirty percent of
depressed patients with diabetes were referred to a
mental health care provider or institution compared
with 5% of non-depressed patients with diabetes in
2002-2004 (OR = 10.7, p < 0.001).
Costs
Mean costs per year in the period 2002-2004 and stan-
dard deviations are presented in Table 4. Costs in all
categories were significantly higher in depressed patients
with diabetes than in non-depressed patients with dia-
betes. Mean total outpatient costs per year in depressed
patients with diabetes were €1039 (743) and more than
two times as high as in non-depressed patients with dia-
betes (€492, SD 434). Mean total outpatient costs
increased with an increasing number of comorbid con-
ditions. Costs in depressed patients with diabetes were
statistically significantly higher than in non-depressed
patients with diabetes (mean difference €547, 95% CI
466 to 635). Mental health care costs accounted for one
third of this difference in costs (mean difference €174,
95% CI 134 to 224).
Table 3 Mean (SD) health care utilization per patient during 3 years (2002-2004) in depressed patients with diabetes
and non-depressed patients with diabetes.
Category Depressed (n = 393) Non-depressed (n = 494)
Contacts with the GP
Consultation 18.9 (14.3) 13.5 (10.6)
Home visit 3.0 (7.7) 0.7 (2.6)
Telephone contact 5.1 (9.8) 2.1 (3.3)
Repeat prescription 31.5 (26.6) 20.2 (19.3)
Physiotherapy 13.3 (20.7) 8.7 (16.3)
Dietician 0.1 (1.3) 0.1 (1.5)
Mental health care
Social worker 0.7 (2.5) 0.2 (1.4)
Psychologist 0.1 (1.3) 0.0 (0.6)
Psychiatrist 7.0 (15.9) 0.8 (5.8)
Psychotherapist 0.1 (0.9) 0 (0)
Regional institute for mental 0.2 (2.1) 0.1 (1.4)
welfare
Outpatient clinic 8.0 (4.1) 6.4 (4.4)
Medication deliveries 158.2 (191.6) 87.4 (131.0)
Table 2 Study sample characteristics, diabetes regimen and co morbidity of depressed patients with diabetes versus
non-depressed patients with diabetes.
Characteristic Depressed (n = 393) Non-depressed (n = 494)
Mean age Years (SD) 59.1 (14.6) 53.1 (13.5)
Sex % Female (n) 61.1 (240) 59.9 (296)
Private insurance % (n) 10.7 (42) 15.4 (76)
Mental health treatment
No mental health treatment % (n) 0 (0) 86.4 (427)
Antidepressants % (n) 62.1 (244) 7.3 (36)
Referral to a psychiatric care provider % (n) 11.5 (45) 4.5 (22)
Antidepressants + referral % (n) 26.5 (104) 1.8 (9)
Diabetes regimen
Oral glucose medication % (n) 51.1 (201) 50.6 (250)
Insulin % (n) 27.2 (107) 30.2 (149)
Oral glucose medication + insulin % (n) 21.6 (85) 19.2 (95)
Comorbidity
0 comorbid conditions % (n) 1.8 (7) 9.9 (49)
1-2 comorbid conditions % (n) 19.6 (77) 38.7 (191)
More than 3 comorbid conditions % (n) 78.6 (309) 51.4 (254)
Bosmans and Adriaanse BMC Health Services Research 2012, 12:46
http://www.biomedcentral.com/1472-6963/12/46
Page 5 of 8
Table 5 shows mean total outpatient costs per year in
the period 2002-2004 in non-depressed patients with
diabetes (constant) and the difference in mean total
costs between depressed and non-depressed patients
with diabetes (bdepression) after correction for possible
confounders in the multilevel analyses. Correction for
comorbidity had the largest impact on the difference in
costs between depressed and non-depressed patients
with diabetes. When comorbidity was divided into three
distinct categories the difference in total annual costs
between depressed and non-depressed patients with dia-
betes changed from €539 (uncorrected, 95% CI 469 to
634) to €463 (corrected, 95% CI 386 to 554).
Discussion
In this study we identified diabetes patients in a primary
care cohort consisting of treated depressed patients and
non-depressed matched controls. We found that total
costs in depressed patients with diabetes were twice as
high as in non-depressed patients with diabetes in the
Netherlands. Even after correction for age, sex, type of
insurance, diabetes treatment, and comorbid conditions
total annual costs in depressed patients were €463
higher than in non-depressed patients, which was statis-
tically significant. Adjustment for comorbidity had the
largest impact on the difference in costs between the
two groups.
Consistent with previous research, our results show
that depression comorbid with diabetes was associated
with significantly higher health care costs than diabetes
alone and that this increase was mainly the result of
increased general medical care and not mental health
care utilization [9,10]. Our study is different from these
studies in the sense that we identified diabetes patients
in a large cohort of depressed primary care patients and
their matched controls, while these other studies
assessed the presence of depression using questionnaires
in participants sampled from a diabetes registry. The
observed increase in health care costs in depressed
patients with diabetes may be caused by unobserved
Table 5 Results of multilevel analyses incorporating a random intercept for clustering of patients within general
practitioners.
Model Constant bdepression* (SE) 95% CI
Crude model 493 539 (41) 469; 634
Only group included
Model 1 521 548 (42) 473; 642
Crude model + age, sex
Model 2 544 542 (43) 461; 634
Model 1 + type of insurance
Model 3 490 540 (43) 459; 634
Model 2 + diabetes treatment
Model 4 370 408 (42) 331; 494
Model 3 + comorbidity1
Model 5 365 463 (42) 386; 554
Model 3 + comorbidity in three categories2
* Difference in total annual costs between depressed patients with diabetes and non-depressed patients with diabetes
1 Limited set of selected comorbidities yes or no: coronary and peripheral vascular disease, hypertension, rheumatologic conditions, hyperlipidemia, cardiac
disease, peptic acid disease, respiratory illness, pain and inflammation, pain, and anxiety and tension.
2 No comorbidity, 1 or 2 comorbid conditions, and 3 or more comorbid conditions
Table 4 Mean (SD) annual costs (unadjusted) in depressed patients with diabetes and non- depressed patients with
diabetes.
Cost category Depressed Non-depressed Difference
Unadjusted (95% CI)
Difference
adjusted
(95% CI)*
GP costs 304 (218) 182 (133) 122 (97; 145) 103 (81; 129)
Physical therapy 102 (158) 68 (125) 34 (17; 55) 33 (14; 53)
Dietician 101 (157) 66 (124) 35 (16; 55) 34 (16; 55)
Mental health care 202 (440) 28 (179) 174 (134; 224) 194 (151; 247)
Outpatient clinic 149 (76) 119 (82) 30 (19; 41) 31 (21; 42)
Medication 182 (247) 30 (160) 152 (125; 182) 157 (129; 186)
Total costs 1039 (743) 492 (434) 547 (466; 635) 553 (468; 641)
* Differences were adjusted for age and sex.
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differences in severity of diabetes or other comorbid
chronic conditions [9]. However, even after we corrected
for comorbid conditions health care costs in depressed
patients with diabetes were significantly higher than in
non-depressed patients with diabetes. An alternative
hypothesis is that depression may interfere with effective
self-care for diabetes leading to higher health care costs
[26] and that effective treatment may result in normal-
ised health care costs. Recent studies evaluating the
cost-effectiveness of systematic identification and treat-
ment of depression in diabetes patients showed that
such interventions may be cost-effective [27,28]. The
Pathways Study showed that a collaborative depression
care program resulted in lower costs over a 5-year per-
iod compared with usual care, although this difference
was not statistically significant [29].
The cost estimates obtained in our study are lower
than in other studies [30,31]. The most likely explana-
tion for this difference is that, since these other studies
depended on GPs for patient selection, patients with
more severe diabetes were included in these studies.
Other explanations may be that not all referrals were
registered by the GPs in their electronic medical record
system and that the national health care utilization rates
may be an underestimation of the number of contacts
for diabetes patients.
Strengths of this study are that we used complete
records of a large cohort of depressed patients and
matched controls in which we identified diabetes
patients. Second, ATC codes of delivered medication
were used to determine the most important covariates, i.
e., diabetes, diabetes treatment and comorbidities. We
expect that this information on delivered medication is
very accurate, since reimbursement by insurance compa-
nies is based on the same data we used for this study.
However, when interpreting these findings one should
also consider some limitations. Only outpatient costs
were considered in this study. However, hospitalization
costs and lost productivity costs due to absenteeism, pre-
senteeism, early retirement and mortality may be sub-
stantially larger than outpatient costs in this population.
From a societal perspective, this is an important limita-
tion. Including these costs will result in higher cost esti-
mates, and, most likely, to a larger difference in costs
between depressed and non-depressed diabetes patients.
Other limitations include the following. First, it was not
possible to discriminate between diabetes mellitus type 1
and type 2, because we used medication data to deter-
mine the presence of diabetes. This means that this study
sample does not include diabetes patients treated by life-
style advices only, which is likely to underestimate the
true diabetes prevalence rates in both groups. Second, we
only had the disposal of data on referrals and not on the
number of contacts following a referral. Therefore, we
had to use national health care utilization data to esti-
mate the number of contacts patients had with other
health care providers than the GP. Patients with depres-
sion and diabetes are likely to require more complex care
than patients with diabetes alone. However, the magni-
tude of this effect is unknown. Therefore, the cost differ-
ence reported in this study is likely to be an
underestimation of the true cost difference. Third,
comorbidity was defined based on medication prescrip-
tions. Thus, it is possible that patients who incidentally
used one of the medications included in the CDS are
incorrectly labelled as having a chronic disease. This may
have overestimated the effect of comorbidity on total
costs. Fourth, for our selection of depressed patients, we
relied on the diagnostic accuracy and treatment by the
GP. Thus, our study did not include depressed persons
who do not visit their GP, depressed persons who are not
recognized as being depressed by the GP and depressed
persons who are recognized as being depressed by the
GP but do not receive a registered diagnosis of depres-
sion or treatment for their depression. Therefore, total
costs of depression among patients with diabetes are
underestimated, while inclusion of depressed persons in
matched controls may lead to an overestimation of mean
costs in controls. Finally, diabetes patients were identified
in depressed patients and non-depressed matched con-
trols. More than one control was available for depressed
patients in younger age categories. As the prevalence of
diabetes increases with age and depressed patients were
older than non-depressed patients as a consequence of
our selection process, it is possible that the prevalence of
diabetes in depressed patients is an overestimation.
In conclusion, our results show that even after adjust-
ment for comorbid conditions health care costs in
depressed patients with diabetes are significantly higher
than in non-depressed patients with diabetes. More longi-
tudinal research in usual clinical practice is needed on the
costs of depression in combination with diabetes with a
distinction into diabetes mellitus 1 and 2. Research should
also indicate whether adequate treatment of depression
among diabetes patients can lead to lower health care
costs in the long term. Finally, the results are of impor-
tance to policy makers. The results of the study clearly
show that the combination of diabetes and depression
leads to markedly increased health care costs. Considering
the expected rise in the prevalence of diabetes, funding
should be made available to disentangle the relationship
between diabetes and depression and to develop treat-
ments to prevent depression in diabetes patients.
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